前列地尔联合阿托伐他汀治疗下肢动脉硬化闭塞症的临床研究  

Clinical Studies Alprostadil with Atorvastatin in Patients with Arteriosclerosis Obliterans Treated

作　　者：吴毅琴[1] 蔡承哲 吕敏清[1] 

机构地区：[1]广州市第十二人民医院,广东广州510620

出　　处：《中外医学研究》2014年第20期53-54,共2页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨前列地尔联合阿托伐他汀治疗下肢动脉硬化闭塞症的临床研究。方法:选取2010年5月-2013年7月笔者所在医院收治的140例下肢动脉硬化闭塞症患者,采用随机数字表法将其分为联合组与对照组,各70例。对照组给予前列地尔治疗,联合组在此基础上联合应用阿托伐他汀治疗,比较两组临床疗效及不良反应发生情况。结果:联合组临床总有效率88.6%明显高于对照组的78.6%,差异有统计学意义(字2=4.627,P=0.016<0.05)。联合组不良反应发生率7.1%与对照组的5.7%比较,差异无统计学意义(P>0.05)。结论:前列地尔联合阿托伐他汀治疗下肢动脉硬化闭塞症安全有效,值得在临床上推广使用。Objective：To study Clinical studies alprostadil with atorvastatin in patients with arteriosclerosis obliterans treated. Method：140 cases of lower extremity arteriosclerosis obliterans from May 2010 to July 2013 in author’s hospital,were randomly divided into combined group and control group,70 cases in each.The control group received alprostadil treatment group on this basis,combined with atorvastatin treatment,incidence rate of two groups of clinical curative effect and adverse reaction.Result：Combined with clinical total effective rate of 88.6%was significantly higher than the control group 78.6%,the difference was statistically significant （χ2=4.627,P=0.016〈0.05）. Compared with the group of adverse reaction was 7.1%and 5.7%in the control group,no significant difference （P〉0.05）.Conclusion：Alprostadil combined with atorvastatin treatment of lower extremity arterial occlusive disease,should be introduced in clinical practice.

关 键 词：前列地尔 阿托伐他汀 下肢动脉硬化闭塞症 

分 类 号：R543.5[医药卫生—心血管疾病]